[1]
|
A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun, “Cancer Statistics,” Cancer Journal for Clinicians, Vol. 59, No. 4, 2009, pp. 225-249.
http://dx.doi.org/10.3322/caac.20006
|
[2]
|
A. L. Warshaw and C. Fernandez-del Castillo, “Pancreatic carcinoma,” The New England Journal of Medicine, Vol. 326, No. 7, 1992, pp. 455-465.
http://dx.doi.org/10.1056/NEJM199202133260706
|
[3]
|
H. A. Burris, M. J. Moore, J. Andersen, et al., “Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial,” Journal of Clinical Oncology, Vol. 15, No. 6, 1997, pp. 2403-1413.
|
[4]
|
D. Li, K. Xie, R .Wolff and J. L. Abbruzzese, “Pancreatic Cancer,” Lancet, Vol. 363, No. 9414, 2004, pp. 10491057. http://dx.doi.org/10.1016/S0140-6736(04)15841-8
|
[5]
|
B. M. Wolpin, P. Kraft, M. Gross, et al., “Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the pancreatic Cancer Cohort Consortium,” Cancer Research, Vol. 70, No. 3, 2010, pp. 1015-1023.
http://dx.doi.org/10.1158/0008-5472.CAN-09-2993
|
[6]
|
N. Kurata, H. Fujita, K. Ohuchida, et al., “Predicting the Chemosensitivity of Pancreatic Cancer Cells by Quantifying the Expression Levels of Genes Associated with the Metabolism of Gemcitabine and 5-Fluorouracil,” International Journal of Oncology, Vol. 39, No. 2, 2011, pp. 473-482.
|
[7]
|
A. K. Fukunaga, S. Marsh, D. J. Murry, T. D. Hurley and H. L. McLeod, “Identification and Analysis of Single-Nucleotide Polymorphisms in the Gemcitabine Pharmacologic Pathway,” The Pharmacogenomics Journal, Vol. 4, No. 5, 2004, pp. 307-314.
http://dx.doi.org/10.1038/sj.tpj. 6500259
|
[8]
|
A. W. Blackstock, H. Lightfoot, L. D. Case, et al., “Tumor Uptake and Elimination of 2’,2’-Difluoro-2’-Deoxycytidine (Gemcitabine) after Deoxycytidine Kinase Gene Transfer: Correlation with in Vivo Tumor Response,” Clinical Cancer Research, Vol. 7, No. 10, 2001, pp. 3263-3268.
|
[9]
|
M. S. Duxbury, H. Ito, M. J. Zinner, S. W. Ashley and E. E. Whang, “RNA Interference Targeting the M2 Subunit of Ribonucleotide Reductase Enhances Pancreatic Adenocarcinoma Chemosensitivity to Gemcitabine,” Oncogene, Vol. 23, No. 8, 2004, pp. 1539-1548.
http://dx.doi.org/10.1038/sj.onc. 1207272
|
[10]
|
H. Fujita, K. Ohuchida, K. Mizumoto, et al., “Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy,” Neoplasia, Vol. 12, No. 10, 2010, pp. 807-817.
|
[11]
|
S. Ohhashi, K. Ohuchida, K. Mizumoto, et al., “DownRegulation of Deoxycytidine Kinase Enhances Acquired Resistance to Gemcitabine in Pancreatic Cancer,” Anticancer Research, Vol. 28, No. 4B, 2008, pp. 2205-2212.
|
[12]
|
E. Giovannetti, M. Del Tacca, V. Mey, et al., “Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine,” Cancer Research, Vol. 66, No. 7, 2006, pp. 3928-3935.
http://dx.doi.org/10.1158/0008-5472.CAN-05-4203
|
[13]
|
J. Spratlin, R. Sangha, D. Glubrecht, et al., “The Absence of Human Equilibrative Nucleoside Transporter 1 is Associated with Reduced Survival in Patients with Gemcitabine-Treated Pancreas Adenocarcinoma,” Clinical Cancer Research, Vol. 10, No. 20, 2004, pp. 6956-6961.
http://dx.doi.org/10.1158/1078-0432.CCR-04-0224
|
[14]
|
Q. Ben, K. Wang, Y. Yuan and Z. Li, “Pancreatic Cancer Incidence and Outcome in Relation to ABO Blood Groups among Han Chinese Patients: A Case-Control Study,” International Journal of Cancer, Vol. 128, No. 5, 2011, pp. 1179-1186. http://dx.doi.org/10.1002/ijc.25426
|
[15]
|
S. Hakomori, “Antigen Structure and Genetic Basis of Histo-Blood Groups A, B and O: Their Changes Associated with Human Cancer,” Biochimica et Biophysica Acta, Vol. 1473, No. 1, 1999, pp. 247-266.
http://dx.doi.org/10.1016/S0304-4165(99)00183-X
|
[16]
|
M. E. Reid and N. Mohandas, “Red Blood Cell Blood Group Antigens: Structure and Function,” Seminars in Hematology, Vol. 41, No. 2, 2004, pp. 93-117.
http://dx.doi.org/10.1053/j.seminhematol. 2004.01.001
|
[17]
|
I. Aird, H. H. Bentall, J. A. Roberts, “A Relationship between Cancer of Stomach and the ABO Blood Groups,” British Medical Journal, Vol. 1, No. 4814, 1953, pp. 799-801. http://dx.doi.org/10.1136/bmj. 1.4814.799
|
[18]
|
G. Edgren, H. Hjalgrim, K. Rostgaard, et al., “Risk of Gastric Cancer and Peptic Ulcers in Relation to ABO Blood Type: A Cohort Study,” American Journal of Epidemiology, Vol. 172, No. 11, 2010, pp. 1280-1285.
http://dx.doi.org/10.1093/aje/kwq299
|
[19]
|
M. A. Gates, B. M. Wolpin, D. W. Cramer, S. E. Hankinson and S. S. Tworoger, “ABO Blood Group and Incidence of Epithelial Ovarian Cancer,” International Journal of Cancer, Vol. 128, No. 2, 2010, pp. 482-486.
http://dx.doi.org/10.1002/ijc.25339
|
[20]
|
S. H. Itzkowitz, M. Yuan, L. D. Ferrell, et al., “Cancer-Associated Alterations of Blood Group Antigen Expression in the Human Pancreas,” Journal of the National Cancer Institute, Vol. 79, No. 3, 1987, pp. 425-434.
|
[21]
|
E. Uchida, M. A. Tempero, D. A. Burnett, Z. Steplewski, P. M. Pour, “Correlative Studies on Antigenicity of Pancreatic Cancer and Blood Group Types,” Cancer Detection and Prevention, Vol. 1, No., 1987, pp. 145-148.
|
[22]
|
P. M. Pour, M. M. Tempero, H. Takasaki, et al., “Expression of Blood Group-Related Antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in Pancreatic Cancer Cells in Comparison with the Patient’s Blood Group Type,” Cancer Research, Vol. 48, No. 19, 1988, pp. 5422-5426.
|
[23]
|
M. H. Schuessler, S. Pintado, S. Welt, et al., “Blood Group and Blood-Group-Related Antigens in Normal Pancreas and Pancreas Cancer: Enhanced Expression of Precursor Type 1, Tn and Sialyl-Tn in Pancreas Cancer,” International Journal of Cancer, Vol. 47, No. 2, 1991, pp. 180-187. http://dx.doi.org/10.1002/ijc.2910470204
|
[24]
|
S. Zhang, H. S. Zhang, C. Cordon-Cardo, et al., “Selection of Tumor Antigens as Targets for Immune Attack Using Immunohistochemistry: II. Blood Group-Related Antigens,” International Journal of Cancer, Vol. 73, No. 1, 1997, pp. 50-56.
http://dx.doi.org/10.1002/(SICI)1097-0215(19970926) 73:1<50::AID-IJC9>3.3.CO;2-O
|
[25]
|
S. Hakomori, “Tumor-Associated Carbohydrate Antigens Defining Tumor Malignancy: Basis for Development of Anti-Cancer Vaccines,” Advances in Experimental Medicine and Biology, Vol. 491, 2001, pp. 369-402.
http://dx.doi.org/10.1007/978-1-4615-1267-7_24
|